From Insight to Action: Risk Factors to Guide Screening and Early Recognition of MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, is a progressive liver disease closely linked to conditions such as obesity, type 2 diabetes, and dyslipidemia. Despite its rising prevalence and emergence as a leading cause of liver-related morbidity, MASH remains underdiagnosed in clinical practice, highlighting the need for early recognition to improve patient outcomes. In the first webinar of a four-part series , join two leading MASH experts as they: Explain the metabolic drivers and mechanisms that underlie MASH development and progression / Highlight key clinical and metabolic risk factors associated with the disease / Offer practical strategies for identifying individuals who may benefit from MASH screening through discussion of a real-world case / Answer your most pressing questions in a dedicated Q & A session.